Ready to take the next winter season, the vaccine against influenza A H1N1, and given that there will be enough doses worldwide, the World Health Organization (WHO) recommended that countries prioritize their application in medical, pregnant women and children older than 6 months who suffer from any chronic disorder.
Each country shall determine the order of precedence according to the specific conditions of each.
Given the global uncertainty persists about the provision of a drug against the virus, on the eve of the upcoming winter season, as well as the efficacy and safety of its implementation, the WHO issued a set of guidelines regarding their use.
The Expert Group on Strategic Advice on Immunization (SAGE) of the health organization met in Geneva in recent days to review the current status of the pandemic, the conditions under which the seasonal vaccine production and the ability to produce the strain is immune.
The experts agreed that the three countries should establish as part of the prevention strategy against the pandemic: protecting the integrity of the health care system and the essential infrastructure of the country, reduce morbidity and mortality and reducing transmission of the virus in communities.
Stressed that countries have a variety of strategies to achieve these objectives, but their choice should take into account the epidemiological situation, resources and capacity to gain access to the vaccine, to launch campaigns to target groups and implement other mitigation measures other than immunization.
Considering that the pandemic is moderately severe, as most patients suffer an impairment refers to spontaneously and leaves no after-effects, specialists noted, however, that groups such as pregnant women, asthmatics and patients with obesity drugs are at increased risk of a severe and even dying from the flu.
Because it is considered unstoppable spread of the virus, the vaccine will be necessary in all countries, so the SAGE stressed the importance of efforts to achieve equity between countries with regard to access to the drug to cope with this pandemic influenza.
The expert group also pointed out that their production through new technologies and their safety has not been extensively evaluated in certain populations, it is very important to implement pharmacovigilance mechanisms of the highest possible quality.
Moreover, it will be imperative that the results of studies of safety and immunogenic capacity and efficiency, made after the entry into the market, are exchanged rapidly in the international community to enable countries to make adjustments to their rules of vaccination .
Subscribe to:
Post Comments (Atom)
Post a Comment